Kinsenoside (Synonyms: (+)-Kinsenoside) |
Catalog No.GC44006
One-Click Copy Product Info
|
Kinsenoside is a bioactive glycoside extracted from Anoectochilus roxburghii.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 151870-74-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Kinsenoside is a bioactive glycoside extracted from Anoectochilus roxburghii. Kinsenoside activates the Nrf2 pathway, inhibits the NF-κB signaling pathway, and modulates the IL-10/STAT3/SOCS3 axis. Kinsenoside can be used in research related to osteoarthritis, diabetic vascular complications, gouty arthritis, and chronic pain[1-4].
In vitro, RAW264.7 macrophages were pretreated with Kinsenoside (3.125–50μg/mL) for 24 hours, followed by stimulation with lipopolysaccharide plus interferon‑γ for 24 hours. Kinsenoside significantly inhibited the expression of pro‑inflammatory factors (interleukin‑6, interleukin‑1β, tumor necrosis factor‑α, interleukin‑12, inducible nitric oxide synthase) and promoted macrophage repolarization from the M1 to the M2 phenotype. Primary mouse chondrocytes were pretreated with Kinsenoside (6.25–25μg/mL) for 24 hours, followed by stimulation with interleukin‑1β (10ng/mL) for 24 hours. Kinsenoside significantly inhibited chondrocyte apoptosis and reduced the inflammatory response[5]. Triple‑negative breast cancer MDA‑MB‑231 and MDA‑MB‑468 cells were treated with Kinsenoside (10–100μM) for 2 days or 14 days. Kinsenoside significantly inhibited cell viability and reduced colony formation. Kinsenoside significantly suppressed lipid droplet formation, decreased triglyceride and total cholesterol accumulation, increased polyunsaturated fatty acid levels, and markedly induced ferroptosis[6].
In vivo, C57BL/6J mice were administered Kinsenoside (10, 20, 30mg/kg; once daily) by oral gavage while receiving CCl₄ (2mL/kg; twice a week) for 8 weeks. Kinsenoside significantly alleviated hepatic histopathological damage, pro‑inflammatory cytokine release, and extracellular matrix deposition[7]. C57BL/6J mice were administered Kinsenoside (20, 40mg/kg; once daily; for 9 consecutive weeks). Four weeks after Kinsenoside treatment began, alcoholic liver injury was induced by an ethanol‑containing liquid diet (4% ethanol) plus 5% CCl₄ (2mL/kg; twice a week; for 5 consecutive weeks). Kinsenoside significantly alleviated hepatic histopathological damage, inflammatory cell infiltration, and collagen fiber deposition, while reducing serum alanine aminotransferase, aspartate aminotransferase, and triglyceride levels[8].
References:
[1] Deng YF, Xu QQ, Chen TQ, et al. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway. Phytomedicine. 2022 Sep;104:154241.
[2] Lu L, Liao J, Xu C, et al. Kinsenoside-Loaded Microneedle Accelerates Diabetic Wound Healing by Reprogramming Macrophage Metabolism via Inhibiting IRE1α/XBP1 Signaling Axis. Adv Sci (Weinh). 2025 Jul;12(26):e2502293.
[3] Qi CX, Zhou Q, Yuan Z, et al. Kinsenoside: A Promising Bioactive Compound from Anoectochilus Species. Curr Med Sci. 2018 Feb;38(1):11-18.
[4] Wang W, Ding Y, Yu C, et al. Kinsenoside attenuates ER stress and inhibits inflammatory responses through IL-10/STAT/SOCS3 pathway in chronic pain relief. Neuropharmacology. 2025 Aug 1;273:110463.
[5] Zhou F, Mei J, Han X, et al. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes. Acta Pharm Sin B. 2019 Sep;9(5):973-985.
[6] Yang Y, Chen D, Zhu Y, et al. Kinsenoside Suppresses DGAT1-Mediated Lipid Droplet Formation to Trigger Ferroptosis in Triple-Negative Breast Cancer. Int J Mol Sci. 2025 Mar 5;26(5):2322.
[7] Xiang M, Liu T, Tian C, et al. Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway. Pharmacol Res. 2022 Mar;177:106092.
[8] Gao L, Chen X, Fu Z, et al. Kinsenoside Alleviates Alcoholic Liver Injury by Reducing Oxidative Stress, Inhibiting Endoplasmic Reticulum Stress, and Regulating AMPK-Dependent Autophagy. Front Pharmacol. 2022 Jan 18;12:747325.
| Cell experiment [1]: | |
Cell lines | MDA-MB-231 and MDA-MB-468 (triple-negative breast cancer cells), and MCF-10A (normal breast epithelial cells) |
Preparation Method | MDA-MB-231 and MDA-MB-468 cells were cultured in DMEM medium supplemented with 10% FBS. MCF-10A cells were cultured in MCF-10A specialized medium with 10% FBS. Cell cultures were provided with a 1% penicillin/streptomycin solution and maintained at 37 °C under a 5% CO2 humidified environment. Cells were treated with Kinsenoside. |
Reaction Conditions | 10-100μM; 2 days or 14 days |
Applications | Kinsenoside significantly inhibited cell viability and colony formation in TNBC cells. Kinsenoside reduced lipid droplet formation, decreased triglyceride and total cholesterol accumulation, and increased polyunsaturated fatty acids levels. Kinsenoside induced ferroptosis, as evidenced by reduced glutathione levels and GPX4、SLC7A11 protein expression, and increased iron accumulation, lipid reactive oxygen species levels, and ACSL4 protein expression. |
| Animal experiment [2]: | |
Animal models | Male 6-week-old C57BL/6J mice |
Preparation Method | Mice received intraperitoneal injection of 10% carbon tetrachloride (CCl4) (dosage: 2mL/kg) two times a week for 8 weeks to induce liver fibrosis. Mice were treated by oral gavage with Kinsenoside (10, 20, 30mg/kg) once a day for 8 weeks. |
Dosage form | 10, 20, 30mg/kg; oral gavage; once daily for 8 weeks |
Applications | Kinsenoside markedly diminished the extent of liver fibrosis with substantial lymphocyte infiltration and collagen deposition. Kinsenoside lowered serum ALT and AST levels and liver index. Kinsenoside lowered the production of pro-inflammatory cytokines like IL-2, IFN-γ, TNF-α, and IL-12, and raised the secretion of anti-inflammatory cytokine IL-10. Kinsenoside reduced NO release. Kinsenoside suppressed expression or release of fibrosis-related proteins, including α-SMA, TGF-β1, Col-I, and TIMP-1 and TIMP-2, but augmented the mRNA and protein level of MMP-13. |
References: | |
| Cas No. | 151870-74-5 | SDF | |
| Synonyms | (+)-Kinsenoside | ||
| Canonical SMILES | OC[C@H]1O[C@@H](O[C@]2([H])CC(OC2)=O)[C@H](O)[C@@H](O)[C@@H]1O | ||
| Formula | C10H16O8 | M.Wt | 264.2 |
| Solubility | DMF: 14 mg/ml,DMSO: 16 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.785 mL | 18.9251 mL | 37.8501 mL |
| 5 mM | 757 μL | 3.785 mL | 7.57 mL |
| 10 mM | 378.5 μL | 1.8925 mL | 3.785 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)